Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A pan-immunotherapy signature to predict intratumoral CD8+ T cell expansions [scTCR_untreated]

ABSTRACT: A pan-immunotherapy signature to predict intratumoral CD8+ T cell expansions [scTCR_untreated]

PROVIDER: PRJNA1301943 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

A pan-immunotherapy signature to predict intratumoral CD8+ T cell expansions [scTCR_immunotherapies]

Project description:A pan-immunotherapy signature to predict intratumoral CD8+ T cell expansions [scTCR_immunotherapies]

| PRJNA1302469 | ENA

A pan-immunotherapy signature to predict intratumoral CD8+ T cell expansions [bulkRNAseq]

Project description:A pan-immunotherapy signature to predict intratumoral CD8+ T cell expansions [bulkRNAseq]

| PRJNA1294142 | ENA

A pan-immunotherapy signature to predict intratumoral CD8+ T cell expansions [bulkTCRseq_FTY]

Project description:A pan-immunotherapy signature to predict intratumoral CD8+ T cell expansions [bulkTCRseq_FTY]

| PRJNA1294143 | ENA

A pan-immunotherapy signature to predict intratumoral CD8+ T cell expansions [bulkTCR_control]

Project description:A pan-immunotherapy signature to predict intratumoral CD8+ T cell expansions [bulkTCR_control]

| PRJNA1294144 | ENA

A pan-immunotherapy signature to predict intratumoral CD8+ T cell expansions [bulkTCR_Trilateral_similarity]

Project description:A pan-immunotherapy signature to predict intratumoral CD8+ T cell expansions [bulkTCR_Trilateral_similarity]

| PRJNA1294384 | ENA

A pan-immunotherapy signature to predict intratumoral CD8+ T cell expansions [bulkTCRseq_Trilateral]

Project description:A pan-immunotherapy signature to predict intratumoral CD8+ T cell expansions [bulkTCRseq_Trilateral]

| PRJNA1294380 | ENA

A pan-immunotherapy signature to predict intratumoral CD8+ T cell expansions [bulkTCRseq_Trilateral]

Project description:Effective cancer immunotherapy relies on the clonal proliferation and expansion of CD8+ T cells in the tumor. However, our insights into clonal expansions are limited, owing to an inability to track the same clones in tumors over time. Here, we developed a multi-site tumor mouse model system to track hundreds of expanding and contracting CD8+ T cell clones over multiple timepoints in tumors of the same individual. Through coupling of clonal expansion dynamics and single-cell RNA/TCR-seq data, we identified a transcriptomic signature in PD-1+Ly108+ precursor exhausted cells that strongly predicts rates of intratumoral clone expansion. The signature correlates with expansion in mice, both with and without immunotherapies, and in patients undergoing PD-1 blockade therapy. Expression of the signature during treatment corresponds with positive clinical outcomes. Downregulation of the signature precedes clone contraction – a phase in which clones contract but maintain revivable precursor exhausted cells in the tumor. LAG-3 blockade re-activates the expansion signature, re-expanding pre-existing clones, including previously contracted clones. These findings reveal how the study of clonal expansion dynamics provide a powerful ‘pan-immunotherapy’ signature for monitoring immunotherapies with implications for their future development.

2025-07-22 | GSE303233 | GEO